bbt002
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 8, 2025 (NCT06944925)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-5INHIBITOR
IL5 inhibitor
- Interleukin-4INHIBITOR
IL4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288554 | Phase 1/Phase 2 (Phase 2) | Sep 5, 2025 | Bambusa Therapeutics |
| NCT06944925 | Phase 1 | May 8, 2025 | Bambusa Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bambusa Therapeutics | For profit | 2 | 2 | 2 | 2025 |
1 organizations
Page 1 / 1